

POSTER PRESENTATION

Open Access

Genetic engineering of T cells with receptors from NY-ESO-1-specific tumor-recognizing CD4⁺ T cell as a novel approach for adoptive T cell therapy

Junko Matsuzaki^{1*}, Takemasa Tsuji¹, Immanuel Luescher², Hiroshi Shiku³, Junichi Mineno⁴, Sachiko Okamoto⁴, Lloyd Old⁵, Protul Shrikant⁶, Sacha Gnjjatic⁷, Kunle Odunsi¹

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015

Background

Tumor antigen-specific CD4⁺ T cells generally orchestrate and regulate innate and adaptive immune cells to provide immune surveillance against malignancy. However, activation of antigen-specific CD4⁺ T cells is restricted at local tumor sites where antigen-presenting cells are frequently dysfunctional, which can cause rapid exhaustion of anti-tumor immune responses. Herein, we characterize anti-tumor effects of a unique human CD4⁺ helper T cell subset that directly recognizes the cytoplasmic tumor antigen, NY-ESO-1, presented by MHC class II (MHC-II) on cancer cells. In addition, we clone the TCR gene from tumor-recognizing CD4⁺ T cells (TR-CD4) and test the function of TCR gene-engineered cells.

Methods

NY-ESO-1-specific CD4⁺ or CD8⁺ T cells were obtained from ovarian cancer patients who received NY-ESO-1 vaccine. Full-length TCR α and β chain genes of TR-CD4 were cloned by 5' RACE PCR. TCR gene was transduced into activated T cells by MSCV-based retroviral vector. The effector function was evaluated against cognate peptide-pulsed target cells or NY-ESO-1⁺MHC-II⁺ cancer cell lines by ELISA, intracellular cytokine staining or CTL assay.

Results

TR-CD4, but not conventional NY-ESO-1-specific CD4⁺ T cells, directly recognized cancer cells in MHC-II-dependent and NY-ESO-1-specific manners. Presentation

of intracellular NY-ESO-1 on MHC-II by cancer cells required non-classical MHC-II antigen presentation mechanisms. Upon direct recognition of cancer cells, TR-CD4 potently induced IFN- γ -dependent growth arrest in cancer cells. In addition, direct recognition of cancer cells triggers TR-CD4 to provide help to NY-ESO-1-specific CD8⁺ T cells by enhancing cytotoxic activity, and improving viability and proliferation. Notably, the TR-CD4 either alone or in combination with NY-ESO-1-specific CD8⁺ T cells significantly inhibited tumor growth *in vivo* in a xenograft model. Finally, retroviral gene-engineering of polyclonally activated T cells with TCR derived from TR-CD4 successfully produced large numbers of functional TR-CD4.

Conclusions

These observations provide mechanistic insights into the role of TR-CD4 in tumor immunity, and suggest that approaches to utilize TR-CD4 will augment anti-tumor immune responses for durable therapeutic efficacy in cancer patients. Large numbers of TR-CD4 that directly recognize cancer cells and enhance CD8⁺ T cell functions can be generated by gene-engineering with TCR from TR-CD4. Antigen-presenting cell-independent provision of CD4-help by TR-CD4 is especially important to enhance durable CD8⁺ T cell anti-tumor functions at the tumor local site. Adoptive T cell therapy using TR-CD4 in combination with CD8⁺ T cells could be a promising strategy for effective eradication of tumors.

Authors' details

¹Roswell Park Cancer Institute, Buffalo, NY, USA. ²Ludwig Center for Cancer Research, Epalinges, Switzerland. ³Mie University Graduate School of Medicine, Tsu, Japan. ⁴TAKARA BIO INC, Otsu, Japan. ⁵Ludwig Institute for

¹Roswell Park Cancer Institute, Buffalo, NY, USA
Full list of author information is available at the end of the article

Cancer Research, New York, NY, USA. ⁶Mayo Clinic, Scottsdale, AZ, USA.
⁷MSSM, New York, NY, USA.

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-P34

Cite this article as: Matsuzaki *et al.*: Genetic engineering of T cells with receptors from NY-ESO-1-specific tumor-recognizing CD4+ T cell as a novel approach for adoptive T cell therapy. *Journal for ImmunoTherapy of Cancer* 2015 **3**(Suppl 2):P34.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

